litlas
Log inCreate account

John H. Sampson

Active 1996–2025

155
Papers
31,511
Citations
101
h-index
153
i10-index

Citations

Citations per year for John H. Sampson1979: 1 citations1986: 1 citations1997: 4 citations1998: 4 citations1999: 9 citations2000: 16 citations2001: 23 citations2002: 30 citations2003: 69 citations2004: 67 citations2005: 71 citations2006: 146 citations2007: 151 citations2008: 198 citations2009: 256 citations2010: 271 citations2011: 227 citations2012: 273 citations2013: 251 citations2014: 321 citations2015: 301 citations2016: 249 citations2017: 403 citations2018: 344 citations2019: 957 citations2020: 1,434 citations2021: 1,533 citations2022: 1,264 citations2023: 1,025 citations2024: 1,490 citations2025: 681 citations2026: 14 citations1980–1985: no citations, so these years are not shown1987–1996: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,539 citing papers, 32% of this breakdownChina: 1,422 citing papers, 12.9% of this breakdownGermany: 680 citing papers, 6.2% of this breakdownUnited Kingdom: 501 citing papers, 4.5% of this breakdownItaly: 473 citing papers, 4.3% of this breakdownFrance: 345 citing papers, 3.1% of this breakdownCanada: 322 citing papers, 2.9% of this breakdownSwitzerland: 316 citing papers, 2.9% of this breakdownNetherlands: 314 citing papers, 2.8% of this breakdownAustralia: 252 citing papers, 2.3% of this breakdownSpain: 234 citing papers, 2.1% of this breakdownJapan: 205 citing papers, 1.9% of this breakdown
0%32%Other 22.1%

Institutions

Fields

  • Medicine57.5%
  • Biochemistry, Genetics and Molecular Biology20.4%
  • Immunology and Microbiology12.1%
  • Neuroscience3.3%
  • Engineering2.8%
  • Materials Science2.4%
  • Other1.5%

Topics

  • Glioma Diagnosis and Treatment13.5%
  • Cancer Immunotherapy and Biomarkers4.7%
  • Immunotherapy and Immune Responses4.7%
  • CAR-T cell therapy research4.6%
  • Brain Metastases and Treatment4.3%
  • Immune cells in cancer3.4%
  • Other64.8%

Coauthors

All papers

Open in search
  1. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

    Authors: David A. Reardon, Alba A. Brandes, Antonio Omuro, Paul Mulholland, Michael Lim, Antje Wick, Joachim M. Baehring, Manmeet S. Ahluwalia, Patrick Roth, Oliver Bähr, Surasak Phuphanich, Juan Manuel Sepúlveda-Sánchez, Paul de Souza, Solmaz Sahebjam, Michael Carleton, Kay Tatsuoka, Corina Taitt, Ricardo Zwirtes, John H. Sampson, Michael Weller - JAMA Oncology 2020 cited by 1,457

  2. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

    Authors: Michael Weller, Nicholas Butowski, David Tran, Lawrence D. Recht, Michael Lim, Hal W. Hirte, Lynn S. Ashby, Laszlo Mechtler, Samuel Goldlust, Fábio M. Iwamoto, Jan Drappatz, Donald M. O’Rourke, Mark Wong, Mark G. Hamilton, Gaetano Finocchiaro, James Perry, Wolfgang Wick, Jennifer Green, Yi He, Christopher D. Turner, Michael Yellin, Tibor Keler, Thomas A. Davis, Roger Stupp, John H. Sampson, Nicholas Butowski, Jian Campian, Lawrence D. Recht, Michael Lim, Lynn S. Ashby, Jan Drappatz, Hal W. Hirte, Fábio M. Iwamoto, Laszlo Mechtler, Samuel Goldlust, Kevin Becker, Gene H. Barnett, Garth Nicholas, Annick Desjardins, Tara Benkers, Naveed Wagle, Morris D. Groves, Santosh Kesari, Zsolt Horváth, Ryan Merrell, Richard Curry, James O’Rourke, David M. Schuster, Mark Wong, Maciej M. Mrugała, Randy Jensen, John Trusheim, Glenn J. Lesser, Karl Bélanger, Andrew E. Sloan, Benjamin Purow, Karen Fink, Jeffrey J. Raizer, Michael Schulder, Suresh Nair, Scott Peak, James Perry, Alba A. Brandes, Michael Weller, Nimish Mohile, Joseph Landolfi, Jon Olson, Gaetano Finocchiaro, Ross Jennens, Paul DeSouza, Bridget A. Robinson, Marka R. Crittenden, Kent C. Shih, Alexandra Flowers, Shirley Ong, Jennifer Connelly, Costas G. Hadjipanayis, Pierre Giglio, Frank E. Mott, David Mathieu, N. Lessard, Sanchez Juan Sepulveda, József Lövey, Helen Wheeler, Po-Ling Inglis, Claire Hardie, Daniela A. Bota, Maciej S. Lesniak, Jana Portnow, Bruce Frankel, Larry Junck, Reid C. Thompson, Lawrence Berk, John Paul McGhie, David Macdonald, Frank Saran, Riccardo Soffietti, Deborah T. Blumenthal, Sá Barreto Costa Marcos André de, Anna K. Nowak and 93 more - The Lancet Oncology 2017 cited by 1,113

  3. Brain immunology and immunotherapy in brain tumours

    Authors: John H. Sampson, Michael D. Gunn, Peter E. Fecci, David M. Ashley - Nature reviews. Cancer 2019 cited by 725

  4. Challenges to curing primary brain tumours

    Authors: Kenneth Aldape, Kevin M. Brindle, Louis Chesler, Rajesh Chopra, Amar Gajjar, Mark R. Gilbert, Nicholas G. Gottardo, David H. Gutmann, Darren Hargrave, Eric C. Holland, David Jones, Johanna A. Joyce, Pamela Kearns, Mark W. Kieran, Ingo K. Mellinghoff, Melinda S. Merchant, Stefan M. Pfister, Steven M. Pollard, Vijay Ramaswamy, Jeremy N. Rich, Giles Robinson, David H. Rowitch, John H. Sampson, Michael D. Taylor, Paul Workman, Richard J. Gilbertson - Nature Reviews Clinical Oncology 2019 cited by 972

  5. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors

    Authors: Pakawat Chongsathidkiet, Christina Jackson, Shohei Koyama, Franziska Loebel, Xiuyu Cui, S. Harrison Farber, Karolina Woroniecka, Aladine A. Elsamadicy, Cosette Dechant, Hanna Kemeny, Luis Sánchez-Pérez, Tooba A. Cheema, Nicholas Souders, James E. Herndon, Jean-Valéry Coumans, Jeffrey I. Everitt, Brian V. Nahed, John H. Sampson, Michael D. Gunn, Robert L. Martuza, Glenn Dranoff, William T. Curry, Peter E. Fecci - Nature Medicine 2018 cited by 664

  6. Recurrent Glioblastoma Treated with Recombinant Poliovirus

    Authors: Annick Desjardins, Matthias Gromeier, James E. Herndon, Nike Beaubier, Dani P. Bolognesi, Allan H. Friedman, Henry S. Friedman, Frances McSherry, Andrea Muscat, Smita K. Nair, Katherine B. Peters, Dina Randazzo, John H. Sampson, Gordana Vlahovic, W.T.A. Harrison, Roger E. McLendon, David M. Ashley, Darell D. Bigner - New England Journal of Medicine 2018 cited by 802

  7. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

    Authors: Hideho Okada, Michael Weller, Raymond Y. Huang, Gaetano Finocchiaro, Mark R. Gilbert, Wolfgang Wick, Benjamin M. Ellingson, Naoya Hashimoto, Ian F. Pollack, Alba A. Brandes, Enrico Franceschi, Christel Herold‐Mende, Lakshmi Nayak, Ashok Panigrahy, Whitney B. Pope, Robert M. Prins, John H. Sampson, Patrick Y. Wen, David A. Reardon - The Lancet Oncology 2015 cited by 763

  8. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy

    Authors: William H. Tomaszewski, Luis Sánchez-Pérez, Thomas F. Gajewski, John H. Sampson - Clinical Cancer Research 2019 cited by 324

  9. CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis

    Authors: Emily Lerner, Karolina Woroniecka, Vincent M. D’Anniballe, Daniel Wilkinson, Aditya Mohan, Selena Lorrey, Jessica Waibl Polania, Lucas P. Wachsmuth, Alexandra Miggelbrink, Joshua Jackson, Xiuyu Cui, Jude Raj, William H. Tomaszewski, Sarah Cook, John H. Sampson, Anoop P. Patel, Mustafa Khasraw, Michael D. Gunn, Peter E. Fecci - Nature Cancer 2023 cited by 138

  10. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

    Authors: Antonio Omuro, Gordana Vlahovic, Michael Lim, Solmaz Sahebjam, Joachim M. Baehring, Timothy F. Cloughesy, Alfredo Voloschin, Shakti Ramkissoon, Keith L. Ligon, Robert Latek, Ricardo Zwirtes, Lewis C. Strauss, Prashni Paliwal, Christopher Harbison, David A. Reardon, John H. Sampson - Neuro-Oncology 2017 cited by 488

  11. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

    Authors: Duane A. Mitchell, Kristen A. Batich, Michael D. Gunn, Min-Nung Huang, Luis Sánchez-Pérez, Smita K. Nair, Kendra L. Congdon, Elizabeth A. Reap, Gary E. Archer, Annick Desjardins, Allan H. Friedman, Henry S. Friedman, James E. Herndon, April Coan, Roger E. McLendon, David A. Reardon, James J. Vredenburgh, Darell D. Bigner, John H. Sampson - Nature 2015 cited by 524

  12. Increased Regulatory T-Cell Fraction Amidst a Diminished CD4 Compartment Explains Cellular Immune Defects in Patients with Malignant Glioma

    Authors: Peter E. Fecci, Duane A. Mitchell, John F. Whitesides, Weihua Xie, Allan H. Friedman, Gary E. Archer, James E. Herndon, Darell D. Bigner, Glenn Dranoff, John H. Sampson - Cancer Research 2006 cited by 620

  13. Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement

    Authors: Stephen Bagley, Shawn Kothari, Rifaquat Rahman, Eudocia Q. Lee, Gavin P. Dunn, Evanthia Galanis, Susan M. Chang, Burt Nabors, Manmeet S. Ahluwalia, Roger Stupp, Minesh P. Mehta, David A. Reardon, Stuart A. Grossman, Erik P. Sulman, John H. Sampson, Simon Khagi, Michael Weller, Timothy F. Cloughesy, Patrick Y. Wen, Mustafa Khasraw - Clinical Cancer Research 2021 cited by 164

  14. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination

    Authors: Kristen A. Batich, Elizabeth A. Reap, Gary E. Archer, Luis Sánchez-Pérez, Smita K. Nair, Robert J. Schmittling, Pam Norberg, Weihua Xie, James E. Herndon, Patrick Healy, Roger E. McLendon, Allan H. Friedman, Henry S. Friedman, Darell D. Bigner, Gordana Vlahovic, Duane A. Mitchell, John H. Sampson - Clinical Cancer Research 2017 cited by 288

  15. Oncolytic virus-derived type I interferon restricts CAR T cell therapy

    Authors: Laura Evgin, Amanda L. Huff, Phonphimon Wongthida, Jill Thompson, Tim Kottke, Jason M. Tonne, Matthew Schuelke, Katayoun Ayasoufi, Christopher B. Driscoll, Kevin G. Shim, Pierce Reynolds, Dileep D. Monie, Aaron J. Johnson, Matt Coffey, Sarah L. Young, Gary E. Archer, John H. Sampson, José S. Pulido, Luis Sanchez Perez, Richard G. Vile - Nature Communications 2020 cited by 118

  16. Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

    Authors: John H. Sampson, Amy B. Heimberger, Gary E. Archer, Kenneth Aldape, Allan H. Friedman, Henry S. Friedman, Mark R. Gilbert, James E. Herndon, Roger E. McLendon, Duane A. Mitchell, David A. Reardon, Raymond Sawaya, Robert J. Schmittling, Weiming Shi, James J. Vredenburgh, Darell D. Bigner - Journal of Clinical Oncology 2010 cited by 808

  17. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

    Authors: David A. Reardon, Annick Desjardins, James J. Vredenburgh, Donald M. O’Rourke, David Tran, Karen Fink, Burt Nabors, Gordon Li, Daniela A. Bota, Rimas V. Lukas, Lynn S. Ashby, J. Paul Duic, Maciej M. Mrugała, Scott Cruickshank, Laura Vitale, Yi He, Jennifer A. Green, Michael Yellin, Christopher D. Turner, Tibor Keler, Thomas A. Davis, John H. Sampson - Clinical Cancer Research 2020 cited by 177

  18. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

    Authors: James M. Schuster, R. K. Lai, Lawrence D. Recht, David A. Reardon, Nina A. Paleologos, Morris D. Groves, Maciej M. Mrugała, Randy L. Jensen, Joachim M. Baehring, Andrew E. Sloan, Gerald E. Archer, D. D. Bigner, Scott Cruickshank, J. A. Green, Tibor Keler, Thomas A. Davis, Amy B. Heimberger, John H. Sampson - Neuro-Oncology 2015 cited by 417

  19. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

    Authors: John H. Sampson, Kenneth Aldape, Gerald E. Archer, April Coan, Annick Desjardins, Allan H. Friedman, Henry S. Friedman, Mark R. Gilbert, James E. Herndon, Roger E. McLendon, Duane A. Mitchell, David A. Reardon, Raymond Sawaya, Robert J. Schmittling, Weiming Shi, James J. Vredenburgh, Darell D. Bigner, Amy B. Heimberger - Neuro-Oncology 2010 cited by 369

  20. Proteomic and immunologic analyses of brain tumor exosomes

    Authors: Michael W. Graner, Óscar Álzate, Angelika M. Dechkovskaia, Jack D. Keene, John H. Sampson, Duane A. Mitchell, Darell D. Bigner - The FASEB Journal 2008 cited by 427

  21. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma

    Authors: Sushma Kunwar, Susan M. Chang, Manfred Westphal, Michael A. Vogelbaum, John H. Sampson, Gene H. Barnett, Mark E. Shaffrey, Zvi Ram, J Piepmeier, Michael D. Prados, David Croteau, Christoph Pedain, Pamela Leland, Syed R. Husain, Bharat Joshi, Raj K. Puri, for the PRECISE Study Group - Neuro-Oncology 2010 cited by 481

  22. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

    Authors: Matthias Gromeier, Michael C. Brown, Gao Zhang, Xiang Lin, Yeqing Chen, Zhi Wei, Nike Beaubier, Hai Yan, Yiping He, Annick Desjardins, James E. Herndon, Frederick S. Varn, Roel G.W. Verhaak, Junfei Zhao, Dani P. Bolognesi, Allan H. Friedman, Henry S. Friedman, Frances McSherry, Andrea Muscat, Eric Lipp, Smita K. Nair, Mustafa Khasraw, Katherine B. Peters, Dina Randazzo, John H. Sampson, Roger E. McLendon, Darell D. Bigner, David M. Ashley - Nature Communications 2021 cited by 124

  23. Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3

    Authors: Teilo Schaller, Kristen A. Batich, Carter M. Suryadevara, Rupen Desai, John H. Sampson - Expert Review of Clinical Immunology 2017 cited by 148

  24. EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss

    Authors: John H. Sampson, Bryan D. Choi, Luis Sánchez-Pérez, Carter M. Suryadevara, David J. Snyder, Catherine Flores, Robert J. Schmittling, Smita K. Nair, Elizabeth A. Reap, Pamela K. Norberg, James E. Herndon, Chien-Tsun Kuan, Richard A. Morgan, Steven A. Rosenberg, Laura A. Johnson - Clinical Cancer Research 2013 cited by 293